[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ChromX Health\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":84},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100555943","differentiation-of-benign-and-malignant-pulmonary-nodules-by-volatile-organic-compounds-in-human-exhaled-breath-100555943",false,"NCT06518655","Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath","Exploratory Study on the Identification of Benign and Malignant Pulmonary Nodules Using Volatile Organic Compounds in Human Exhaled Breath","Inclusion Criteria:\n\n* 18-80 years old;\n* Pulmonary nodules were detected through low-dose spiral CT, chest CT conventional scan, or high-resolution thin-layer CT examination, with a maximum diameter of 5-30 mm, including solid nodules and ground glass nodules;\n* Patients require pulmonary nodule resection to define the type of nodule pathology;\n* The Patients have not yet used any drugs for tumor treatment;\n* Patients and\u002For family members are able to understand the research protocol and are willing to participate in this study, providing written informed consent.\n\nExclusion Criteria:\n\n* The maximum diameter of pulmonary nodules is greater than 30 mm;\n* Patients are unable to determine the pathological diagnosis of pulmonary nodules after surgical resection or biopsy;\n* Patients with recurrent lung cancer;\n* Patients who have undergone lung transplantation or lobectomy;\n* Individuals who currently or have a history of malignant tumors;\n* Patients in the acute phase of inflammation or in need of intensive care in the above selected disease groups;\n* Individuals with severe liver and kidney dysfunction;\n* Mental illness patients (such as severe dementia, schizophrenia, severe depression, manic depressive psychosis, etc.);\n* Confirmed HIV patients;\n* Pregnant or lactating women;\n* Patients or family members are unable to understand the conditions and objectives of this study.\n* The patient is unwilling or unable to personally sign the informed consent form.",true,"ALL","18 Years","80 Years",{"count":21,"type":22},3000,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) markers. This model aims to accurately differentiate benign from malignant nodules in individuals harboring pulmonary nodules. The primary objectives it strives to accomplish are:\n\n1. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in distinguishing benign and malignant pulmonary nodules.\n2. To evaluate the diagnostic effectiveness of an AI model that employs exhaled breath VOC biomakers to identify specific types of malignant nodules, including lung adenocarcinoma, lung squamous cell carcinoma, and small cell lung cancer.\n3. To explore and identify key characteristic VOCs combinations that are associated with EGFR site mutations in malignant nodules, further modeling and evaluating the classification performance.\n\nBy utilizing this comprehensive approach, the study hopes to contribute significantly to early detection and accurate classification of pulmonary nodules, ultimately leading to improved patient care and treatment outcomes.",[26,27,28],"Pulmonary Nodules, Multiple","Pulmonary Nodules, Solitary","Lung Cancer",[30,28,31,32],"Pulmonary Nodules","Volatile Organic Compounds","Human Exhaled Breath","RECRUITING","2025-12-18",{"date":36,"type":37},"2025-12-24","ACTUAL",{"date":39,"type":37},"2024-06-30",{"date":41,"type":22},"2027-06-30",{"name":43,"class":44},"ChromX Health","INDUSTRY",15,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":56,"conditions":57,"keywords":73,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":81,"leadSponsor":82,"locationsCount":83},"100556693","identification-of-multiple-pulmonary-diseases-using-volatile-organic-compounds-biomarkers-in-human-exhaled-breath-100556693","NCT06528418","Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath","Exploration and Study on the Identification of Various Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath","Inclusion Criteria:\n\n* Males or females, age must be 18 years old or above.\n* Patients must meet the CT imaging diagnostic criteria for different lung diseases, and patients must be able to provide electronic versions of CT image data.\n* Patients must have a clear clinical diagnosis.\n* All participants must sign a written informed consent form.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Individuals with a history of cancer other than lung disease.\n* Individuals who have undergone organ transplants or non-autologous (allogeneic) bone marrow or stem cell transplants.\n* Individuals with other severe organic diseases or mental illnesses.\n* Individuals with metabolic diseases such as diabetes, hyperlipidemia, etc.\n* Any other condition that researchers deem unsuitable for participation in this clinical trial.","100 Years",{"count":55,"type":22},10000,"The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) marker molecules. This model aims to accurately diagnose mutiple pulmonary diseases. The primary objectives it strives to accomplish are:\n\n1. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in diagnose several common pulmonary diseases.\n2. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in diagnose more pulmonary diseases.",[28,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72],"Lung Infection","COPD","Bronchitis","Pulmonary Fibrosis","Pulmonary Embolism","Pulmonary Arterial Hypertension","Pulmonary Tuberculosis","Pulmonary Abscess","Emphysema","Lung Injury","Cystic Fibrosis of the Lung","Bronchial Asthma","Bronchiectasis","Interstitial Lung Disease","Preserved Ratio Impaired Spirometry",[74,31,32,75,76],"Pulmonary Disease","micro Gas Chromatography-photoionisation","detector (μGC-PID) system","2025-03-23",{"date":79,"type":37},"2025-03-26",{"date":39,"type":37},{"date":41,"type":22},{"name":43,"class":44},1,""]